|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:bioavailability
|
40%
|
|
gptkbp:brand
|
gptkb:Revatio
gptkb:Viagra
|
|
gptkbp:CASNumber
|
139755-83-2
|
|
gptkbp:drugClass
|
phosphodiesterase type 5 inhibitor
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
renal
fecal
|
|
gptkbp:hasInChIKey
|
PUVRQGZPVYWZSR-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C17H19N3O3
|
|
gptkbp:hasOriginatorCompany
|
gptkb:Pfizer
|
|
gptkbp:hasSMILES
|
CCCN1C2=C(C(=N1)N(C=N2)C)C3=CC(=C(C=C3)S(=O)(=O)N4CCN(CC4)C)OCC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL19010
|
|
gptkbp:indication
|
erectile dysfunction
pulmonary arterial hypertension
|
|
gptkbp:IUPACName
|
gptkb:1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits phosphodiesterase type 5 (PDE5)
|
|
gptkbp:metabolism
|
hepatic (CYP3A4, CYP2C9)
|
|
gptkbp:molecularWeight
|
313.35
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL19010
DB00203
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
dyspepsia
flushing
visual disturbance
|
|
gptkbp:status
|
approved
|
|
gptkbp:synonym
|
gptkb:Sildenafil
|
|
gptkbp:target
|
PDE5A
|
|
gptkbp:bfsParent
|
gptkb:VER-155008
|
|
gptkbp:bfsLayer
|
8
|